HomeMarketsSharesUSANA Health Sciences Inc

Trade USANA Health Sciences Inc - USNA CFD

Market is not available at the momentMarket information is presented
as of 2026-10-09T19:46:04+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.07
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.022179 %
(-$1.11)

Trade size with leverage ~ $5,000.00

Money from leverage ~ $$4,000.00


-0.02218%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000043 %
(-$0.00)

Trade size with leverage ~ $5,000.00

Money from leverage ~ $$4,000.00


-0.00004%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close14.59
Open14.25
1-Year Change-46.15%
Day's Range14.23 - 14.85

Trade USANA Health Sciences Inc - USNA

About USANA Health Sciences, Inc.

USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, Foods, Personal Care and Skincare and All Other. Its USANA Nutritionals Optimizers product line consists of supplements designed to meet individual health and nutritional needs. Its Essentials/CellSentials product line includes vitamin and mineral supplements that provides a total body nutrition for every age group beginning with children 13 months of age. Its Foods product line includes meal replacement shakes, snack bars, and other related products that provides macro-nutrition. Its Personal Care and Skincare product line includes its science-based personal care products and Celavive, its skincare system. Its All Other product line includes materials and online tools that are designed to assist its associates in building their businesses and in marketing its products.

Financial summary

BRIEF: For the fiscal year ended 01 January 2022, USANA Health Sciences, Inc. revenues increased 5% to $1.19B. Net income decreased 7% to $116.5M. Revenues reflect USANA® Nutritionals segment increase of 6% to $1.02B, USANA Foods segment increase of 5% to $83.1M, China segment increase of 6% to $563.5M, North Asia segment increase of 13% to $129.9M. Net income was offset by Associate incentives increase of 6% to $519.3M (expense), Selling/General/Admin.

Equity composition

Common Stock $.001 Par, 03/11, 50M auth., 15,843,837 o/s. Insiders control approx 53.74%. 1/93, spun-off from Gull Laboratories, Inc. 10/03, 8/98, 2-for-1 stock splits.

Latest shares articles

A GameStop store in Portland, Oregon
GameStop stock forecast: debt exchange, Q2 profit
GameStop is a US video-game retailer. In Q2 fiscal 2026, net sales fell to $790.2m, while operating income rose to $160.2m. Explore third-party GME price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:06, 7 October 2026
Freenet stock forecast
Freenet stock forecast: revenue rises, EBITDA falls
Freenet reported first-half 2026 revenue of €1,512.9 million, up 24.7% year on year, while adjusted EBITDA fell 5.9% to €242.2 million and 2026 guidance was maintained. Explore third-party FNTN price targets and technicals. Past performance is not a reliable indicator of future results.
12:41, 7 October 2026
Hims & Hers Health stock forecast
Hims & Hers Health stock forecast: FDA GLP-1 warning
Hims & Hers Health is a US telehealth company. In August 2026, the FDA issued a warning concerning unapproved compounded GLP-1 weight-loss drugs. Explore third-party HIMS price targets and technical analysis. Past performance is not a reliable indicator of future results.
12:18, 7 October 2026
Arm Holdings stock forecast
Arm Holdings stock forecast: Haas flags AI demand
Arm Holdings is a UK-based semiconductor company. Chief executive Rene Haas said AI and data-centre demand showed no signs of slowing. Explore third-party ARM price targets and technical analysis. Past performance is not a reliable indicator of future results.
09:43, 6 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready